STING1 and neoplasm: As an endogenous member of the cGAS-STING signalling pathway, cGAMP exhibits significant potential as a STING agonist in anti-tumour therapy, as CAR-T cells generated using cGAMP display enhanced anti-tumour capacity in breast cancer (Xu et al., 2021; Su et al., 2022).